Education
About Us
Working with TipRanks
Follow Us
Grifols SA (GRFS)
NASDAQ:GRFS
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.22Last Year’s EPS
0.02Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 24.93%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Positive
Grifols reported strong Q1 2025 performance with record revenue and growth, particularly in the immunoglobulin franchise. Despite challenges like negative free cash flow due to a strategic payment and temporary albumin issues, the company showed robust adjusted EBITDA and continued deleveraging efforts. The results are ahead of plan even amidst macroeconomic uncertainties and IRA impacts.Company Guidance
During the Q1 2025 earnings call, Grifols executives highlighted a robust start to the fiscal year, reporting revenue of EUR 1.786 billion—a 7.4% increase on a constant currency basis, which rises to 10% on a like-for-like basis. Adjusted EBITDA reached EUR 400 million, marking a 14.2% increase at constant currency and nearly 22% like-for-like. Despite a negative free cash flow of EUR 44 million, attributed to a EUR 79 million payment to ImmunoTek, the company achieved a year-on-year improvement in free cash flow by over EUR 200 million. The revenue growth was primarily driven by the biopharma segment, with the immunoglobulin franchise experiencing a 17.5% revenue increase on a constant currency basis. Management reaffirmed their 2025 guidance, anticipating continued revenue growth, enhanced profitability, and free cash flow improvements, underpinned by strategic initiatives and market dynamics.Record Revenue and Growth in Q1 2025
Revenue in Q1 2025 reached EUR1.786 billion, a 7.4% increase on a constant currency basis. On a like-for-like basis, revenue increased by 10%.
Strong Adjusted EBITDA Performance
Adjusted EBITDA reached EUR400 million, an improvement of 14.2% at constant currency. Like-for-like, it grew by close to 22%.
Impressive Growth in Immunoglobulin Franchise
The immunoglobulin franchise achieved 17.5% growth in revenue at constant currency and like-for-like, with subcutaneous IG growing an impressive 91% at constant currency.
Improvement in Free Cash Flow
Free cash flow for the quarter was negative EUR44 million, but there was a year-on-year improvement of more than EUR200 million.
Continued Deleveraging
Leverage improved slightly from 4.6 times to under 4.5 times, marking a priority for the company.
GRFS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GRFS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $7.10 | $7.73 | +8.87% |
Feb 26, 2025 | $7.38 | $7.94 | +7.59% |
Nov 07, 2024 | $9.05 | $9.50 | +4.97% |
Jul 30, 2024 | $7.71 | $7.75 | +0.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Grifols SA (GRFS) report earnings?
Grifols SA (GRFS) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is Grifols SA (GRFS) earnings time?
Grifols SA (GRFS) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GRFS EPS forecast?
GRFS EPS forecast for the fiscal quarter 2025 (Q2) is 0.22.